Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 294 participants.

Also called NCT03772041

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 294 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03772041
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03772041. Randomized; double masking; primary purpose treatment. Start 2019-01-16 (actual); primary completion 2020-07-21 (actual). Results posted on 2021-08-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure
Condition
Congestive Heart Failure
Intervention (Drug)
OPC-61815
Intervention (Drug)
Tolvaptan Tab 15 MG
Lead sponsor
Otsuka Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03772041
Content hash
dc0139bd17c06b1cee1de4ba8870dd0ca6790ef6269a03a139c2297b800693b4